mFast-SeqS as a Monitoring and Pre-screening Tool for Tumor-Specific Aneuploidy in Plasma DNA
- 18 October 2016
- book chapter
- Published by Springer Nature
- Vol. 924, 147-155
Abstract
Recent progress in the analysis of cell-free DNA fragments (cell-free circulating tumor DNA, ctDNA) now allows monitoring of tumor genomes by non-invasive means. However, previous studies with plasma DNA from patients with cancer demonstrated highly variable allele frequencies of ctDNA. Comprehensive genome-wide analysis of tumor genomes is greatly facilitated when plasma DNA has increased amounts of ctDNA. In order to develop a fast and cost-effective pre-screening method for the identification of plasma samples suitable for further extensive qualitative analysis, we adapted the recently described FAST-SeqS method. We show that our modified FAST-SeqS method (mFAST-SeqS) can be used as a pre-screening tool for an estimation of the ctDNA percentage. Moreover, since the genome-wide mFAST-SeqS z-scores correlate with the actual tumor content in plasma samples, changes in ctDNA levels associated with response to treatment can be easily monitored without prior knowledge of the genetic composition of tumor samples.Keywords
This publication has 18 references indexed in Scilit:
- Rapid Identification of Plasma DNA Samples with Increased ctDNA Levels by a Modified FAST-SeqS ApproachClinical Chemistry, 2015
- The dynamic range of circulating tumor DNA in metastatic breast cancerBreast Cancer Research, 2014
- Liquid Biopsies: Genotyping Circulating Tumor DNAJournal of Clinical Oncology, 2014
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human MalignanciesScience Translational Medicine, 2014
- Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencingProceedings of the National Academy of Sciences, 2013
- Circulating tumor cells and DNA as liquid biopsiesGenome Medicine, 2013
- Complex Tumor Genomes Inferred from Single Circulating Tumor Cells by Array-CGH and Next-Generation SequencingCancer Research, 2013
- Establishment of tumor‐specific copy number alterations from plasma DNA of patients with cancerInternational Journal of Cancer, 2013
- Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel SequencingClinical Chemistry, 2013
- Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNAScience Translational Medicine, 2012